Shin Nippon Biomedical Laboratories, Ltd. (2395) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

insource Co., Ltd.

Mitsubishi Research Institute, Inc.

SBS Holdings, Inc.

Prestige International Inc.

GMO Financial Gate, Inc.

Bengo4.com, Inc.

INTAGE HOLDINGS, Inc.

TRYT, Inc.

Shin Nippon Biomedical Laboratories, Ltd.

eGuarantee, Inc.

TKP Corp.

Why is Shin Nippon Biomedical Laboratories, Ltd. ?

High Management Efficiency with a high ROCE of 11.92%

Healthy long term growth as Net Sales has grown by an annual rate of 17.36% and Operating profit at 15.06%

Negative results in Jun 25

INTEREST COVERAGE RATIO(Q) Lowest at 697.98
RAW MATERIAL COST(Y) Grown by 13.31% (YoY)
DEBT-EQUITY RATIO (HY) Highest at 70.43 %

With ROCE of 4.18%, it has a very attractive valuation with a 1.26 Enterprise value to Capital Employed

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 23.62%, its profits have fallen by -10.7%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shin Nippon Biomedical Laboratories, Ltd. should be less than 10%
Overall Portfolio exposure to Miscellaneous should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shin Nippon Biomedical Laboratories, Ltd. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Shin Nippon Biomedical Laboratories, Ltd.

23.62%

0.94

43.60%

Japan Nikkei 225

28.54%

1.11

25.75%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

17.36%

EBIT Growth (5y)

15.06%

EBIT to Interest (avg)

26.69

Debt to EBITDA (avg)

1.88

Net Debt to Equity (avg)

0.85

Sales to Capital Employed (avg)

0.46

Tax Ratio

19.10%

Dividend Payout Ratio

42.27%

Pledged Shares

Institutional Holding

ROCE (avg)

12.04%

ROE (avg)

24.18%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.40

EV to EBIT

30.12

EV to EBITDA

15.02

EV to Capital Employed

1.26

EV to Sales

2.41

PEG Ratio

Dividend Yield

ROCE (Latest)

4.18%

ROE (Latest)

12.32%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET SALES(HY)

At JPY 16,656.11 MM has Grown at 18.84%

NET PROFIT(Q)

At JPY 265.21 MM has Grown at 116.32%

-14What is not working for the Company

INTEREST COVERAGE RATIO(Q)

Lowest at 697.98

RAW MATERIAL COST(Y)

Grown by 13.31% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 70.43 %

INTEREST(Q)

Highest at JPY 57.82 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 6.23 %

Here's what is working for Shin Nippon Biomedical Laboratories, Ltd.

Net Sales

At JPY 16,656.11 MM has Grown at 18.84%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Net Profit

At JPY 265.21 MM has Grown at 116.32%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

Here's what is not working for Shin Nippon Biomedical Laboratories, Ltd.

Interest Coverage Ratio

Lowest at 697.98

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest

Highest at JPY 57.82 MM

in the last five periods and Increased by 6.01% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Profit Margin

Lowest at 6.23 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Debt-Equity Ratio

Highest at 70.43 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 13.31% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Non Operating Income

Highest at JPY 2.21 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income